

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/036,445	01/07/2002	Eric C. Martin	WO-370.009	4916
7590 05/03/2004			EXAMINER	
MILBANK, TWEED, HADLEY AND MCCLOY LLP			HO, UYEN T	
INTERNATIO	NAL SQUARE BUILDII	NG		
1825 EYE STREET, N.W. SUITE 1100 WASHINGTON, DC 20006			ART UNIT	PAPER NUMBER
			3731	
			DATE MAILED: 05/03/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/036,445	MARTIN, ERIC C.			
		Examiner	Art Unit			
		(Jackie) Tan-Uyen T. Ho	3731			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
2a)∐						
Disposition of Claims						
 4) Claim(s) 1-49 is/are pending in the application. 4a) Of the above claim(s) 35-43 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-34 and 44-49 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 						
Applicat	ion Papers					
10)	The specification is objected to by the Examing The drawing(s) filed on is/are: a) and a Applicant may not request that any objection to the Replacement drawing sheet(s) including the corrupt The oath or declaration is objected to by the	ccepted or b) objected to by the he drawing(s) be held in abeyance. Se ection is required if the drawing(s) is ob-	ee 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2) Notice 3) Infor	ot(s) Dee of References Cited (PTO-892) Dee of Draftsperson's Patent Drawing Review (PTO-948) The mation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Der No(s)/Mail Date 01/07/02	4) Interview Summar Paper No(s)/Mail D 5) Notice of Informal 6) Other:				

Application/Control Number: 10/036,445 Page 2

Art Unit: 3731

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-34, 44-49, drawn to a bifurcated stent, classified in class 623,

subclass 1.35.

II. Claims 35-43, drawn to method for facilitating retrograde supply of oxygenate blood from a left ventricle to heart tissue via a coronary sinus,

classified in class 623, subclass 1.35.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used with a different process for example the method of treating a bifurcated section in vascular system of a patient.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject

matter, restriction for examination purposes as indicated is proper.

During a telephone conversation with Mr. Yim on 4/27/04 a provisional election was made with traverse to prosecute the invention of Group I, claims 1-34, 44-49.

Affirmation of this election must be made by applicant in replying to this Office action.

Claims 35-43 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Information Disclosure Statement

5. The information disclosure statement (IDS) submitted on 01/07/2002 is acknowledged and considered.

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-34 and 44-49 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Martin (5,653,743) see figure 1 and col. 2, line 49 to col. 3, line 39. Note: The introductory statement of intended use and all other functional statements have been carefully considered but are deemed not to impose any structural limitations on the claims distinguishable over the Martin's device which is capable of being used as claimed if one desires to do so.

Conclusion

7. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Martin (6,562,066) discloses a stent for arterialization of the coronary sinus and retrograde perfusion of the myocardium an Frid (6,149,682) discloses a bifurcated stent-graft.

Application/Control Number: 10/036,445

Art Unit: 3731

8. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to (Jackie) Tan-Uyen T. Ho whose telephone number is

(703) 306-3421. The examiner can normally be reached on MULTIFLEX Mon. to Sat...

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Michael J. Milano can be reached on (703) 308-2496. The fax phone

number for the organization where this application or proceeding is assigned is 703-

872-9306.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

(Jackie) Tan-Uyen T. Ho

Geerer

Page 4

Patent Examiner

Art Unit 3731

April 28, 2004